MDGN 201

Drug Profile

MDGN 201

Alternative Names: Epodure™; Erythropoietin gene therapy - Aevi Genomic Medicine; MDGN 201 TARGTepo secreting EPO; MDGN-201; TARGTEPO

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Medgenics
  • Developer Aevi Genomic Medicine
  • Class Antianaemics; Erythropoietins; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaemia
  • Preclinical Beta-thalassaemia; Myelodysplastic syndromes

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 01 Sep 2016 Medgenics completes a phase II trial in Anaemia in USA (NCT02468414)
  • 01 Jun 2016 Medgenics completes a phase II trial for Anaemia in Israel (NCT02378662)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top